Health Condition 1: null- hypercholesterolaemia
Conditions
Interventions
None listed
Sponsors
Sanofi Synthelabo India Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient receiving a lipid-modifying therapy for atleast 3 months with a LDL-C value performed less than 12 months AND under the same lipid-modifying treatment (same drugs, same doses) received for at least 3 months at the time of sample 2. Patient agrees to participate in the study by giving written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patient currently participating in a clinical trial 2.Past use of a PCSK9 inhibitor within 6 months prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients reaching LDL-C targets as defined by the ESC/EAS guidelines for the management of dyslipidemia (2011), in patients at very high, high and moderate CV risk.Timepoint: Visit 1 As this is a cross sectional study with no follow-ups. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Percentage of patients reaching LDL-C targets as defined by the ESC/EAS guidelines for the management of dyslipidemia (2011), by physiciansâ?? specialty 2.Description of Patientâ??s profiles 3.Investigatorâ??s assessment of LDL-C target and patientâ??s level of CV risk 4. Patients at the maximum tolerated dose of statin 5.Physicianâ??s characteristics 6.Health-care resourcesâ?? consumptioTimepoint: Visit 1. since this is a cross-sectional study with only one visit and no follow-ups hence all assessments will be done in the first visit. | — |
Countries
Algeria, Argentina, Bangladesh, Brazil, Colombia, Israel, Kuwait, Lebanon, Mexico
Contacts
Public ContactMr Raviteja Adapa
Sanofi Synthelabo India Limited
Outcome results
None listed